Sagility India Limited
(Formerly Sagility India Private Limited)
Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, 
Bommanahalli, Bengaluru – 560068 Karnataka India
Corporate Identification Number: L72900KA2021PLC150054
Tel. No.: 080-71251500, Website: www.sagilityhealth.com
Date: July 30, 2025
To, 
The Manager 
Listing Department 
National Stock Exchange (NSE) 
Exchange Plaza, 5th Floor 
Plot No. C/1, G-Block 
Bandra-Kurla Complex 
Bandra (E), Mumbai - 400 051 
Symbol: SAGILITY
To,
The Manager 
Listing Department 
Bombay Stock Exchange (BSE) 
Phiroze Jeejeebhoy Towers 
Dalal Street Mumbai - 400 001 
Scrip Code:544282
Dear Sir/Ma’am, 
Subject: Submission of Investor Presentation to be made to investors on July 30, 2025, pursuant 
to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015
In continuation to our letter dated July 16, 2025, we are enclosing herewith the presentation to be made 
to Investors on the Financial Results of Sagility India Limited for the quarter ended June 30, 2025,
scheduled today i.e., on Wednesday, July 30, 2025 at 7:30PM (IST).
The details are also being made available on the Company’s website https://sagilityhealth.com/
This is for your kind information and record.
Thanking You, 
For Sagility India Limited 
Satishkumar Sakharayapattana Seetharamaiah   
Company Secretary & Compliance Officer   
M. No: A16008
Encl: a/a

Investor Deck – Q1 FY26
July 30, 2025

Safe Harbour
Certain statements in this release concerning Sagility’ future growth prospects may be seen as forwardlooking statements, which involve a number of risks and uncertainties that could cause the actuals to differ 
materially from such statements. Sagility does not undertake to update any such statement that may have 
been made from time to time by or on behalf of the company..
2

Q1 FY26 Performance Highlights
Note: 
Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
*Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis
► Sagility has been named a Leader by Avasant in both - the Healthcare Payer Business Process Transformation 2025 RadarView and in the 
Clinical and Care Management Business Process Transformation 2025 RadarView
► Sagility won the ‘Most Preferred Workplace FY’26’ award by Marksmen Daily
₹ 15,389 
million
Organic Y-o-Y 
growth
17.9%
15.4 % at Constant 
Currency
Y-o-Y growth
25.8%
23.1 % at Constant 
Currency
₹ 3,687 
million
Margin %
24.0%
Y-o-Y 
growth %
26.5%
₹ 1,997 
million
Margin %
13.0%
Y-o-Y 
growth %
38.0%
Headcount
39,917
Attrition*
27.6%
► 17.9% Y-o-Y organic growth in Q1 FY26 driven by expansion from existing 
clients, while new wins are expected to further strengthen momentum in FY26
► $32 M (potential steady state ACV) of new business & expansion won in Q1 
FY26
► Expansion and new SOWs from 18 existing clients in Q1 FY26
► 4 new clients onboarded in Q1
► Helping set-up a GCC for a client on a BOT model
► Operations remain robust, driven by strong performance across key metrics
Clinicians & 
Technology heads 
3200+

Quarterly KPIs
4
Q1 FY26 Q4 FY25 Q1 FY25 YoY%
Revenue from Operation (in INR Million) 15,389 15,685 12,233 25.8%
Revenue by Vertical Split
By Payer % 88.4% 89.7% 89.1%
By Provider % 11.6% 10.3% 10.9%
Growth in revenue from operation (%) 25.8% 22.2% 9.6%
Adjusted EBITDA (in INR Million) 3,687 4,176 2,916 26.5%
Adjusted EBITDA % 24.0% 26.6% 23.8%
Adjusted PAT (in INR Million) 1,997 2,398 1,447 38.0%
Adjusted PAT % 13.0% 15.3% 11.8%
Total Number of Employees 39,917 39,409 35,858 11.3%
Voluntary attrition rate* (%) 27.6% 32.5% 27.3%
Note: 
Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis

Annual KPIs
5
Q1 FY26 FY25 FY24 FY23
Number of Client groups*
Active 77 75 44 35
Number of new client addition (Gross) 4 38 13 7
Delivery sites
Number of delivery sites 33 33 30 27
New site addition (Gross) 2 10 4 2
TTM Jun 25 FY25 FY24 FY23
Client groups contribution to revenues
Top 3 Client % 64.7% 66.2% 68.3% 72.4%
Top 5 Client % 76.3% 77.9% 79.2% 80.6%
Top 10 Client % 89.4% 90.5% 91.4% 90.7%
Number of Million-dollar client groups
Number of clients contributing more than US$20 million 7 7 5 4
Number of clients contributing to US$5 - US$20 million 6 6 7 7
Number of clients contributing to US$1 - US$5 million 17 12 12 12
Number of clients contributing less than US$1 million 47 50 20 12
* Client groups comprise client entities together with their affiliates. 

Market Updates
6
Market Changes Impact on Payer/ Provider Likely Impact on Sagility
One Big Beautiful Bill – Cuts in 
Federal Medicaid Spending 
► Revenue and margin are expected to be 
impacted for both Payers (due to drop in 
Medicaid Memberships and Medicaid 
funding cuts) and Providers (due to rising 
uninsured populations and lower 
reimbursement rates).
► Low exposure to Medicaid ( mid-single digits). 
Minimal impact of drop in Membership 
► Increase in outsourcing by Payers & Providers to 
manage costs.
Growing adoption of generative and
agentic AI
► Deep healthcare expertise and the continued 
investments in building AI use cases in Healthcare, 
positions Sagility to deliver better business 
outcomes through lower cost and better end 
customer experience
► GenAI is gaining ground though Adoption is 
gradual. Emerging use cases. Domain expertise 
is the differentiator to driving meaningful 
outcomes
Rising Medicare utilization rates 
impacting
profitability
► This is expected to strain Payer margins; 
however, CMS increased MA payments by 
5.06% for CY2026
► Increase in outsourcing to manage costs better; 
however, pricing pressure to increase
► Strong tailwinds for higher outsourcing in clinical 
segment
Tariffs ► Likely tariff driven increase in cost of 
imported medical equipment & 
Pharmaceuticals. Providers more exposed to 
Tariff risks than payers. 
► No tangible impact 

Nurse Assist: Clinical reviews by enabling 
automated understanding and application 
of medical necessity guidelines across 
unstructured medical records
Appeals assist: AI driven real-time support system 
that classifies appeals, extracts information, helps in 
decision making and that helps improve star ratings 
for payors and for providers, analyses denial 
reasons, checks medical records, determines 
medical necessities and generate appeal letters
Engagement Audit and analytics: Using 
AI in engagement automation, audit and 
business intelligence solution for multichannel interactions
Contract Validation: AI based extraction and 
normalization of terms from complex payerprovider contracts
In addition, we are building Agentic AI solutions to transform the way we run our business; Agentic AI collaborators will enhance our 
recruitment and training outcomes, lowering costs and helping us to serve our clients better
Client Use cases: As on date, we have deployed roughly 18 AI based use-cases across 8 clients. We are also working on 15+ additional use 
cases that are relevant to the work that we currently do for our clients. Some examples below:
Accelerating Value Delivery with AI
7

Financial Highlights

Q1 FY26 Financial Highlights
9
Strong Q1 FY26 Performance
₹ 15,389 million
Organic Y-o-Y growth %
17.9%
15.4 % at Constant Currency
Y-o-Y growth %
25.8%
23.1 % at Constant Currency
₹ 3,687 million
Margin %
24.0%
Y-o-Y growth %
26.5%
₹ 1,997 million
Margin %
13.0%
Y-o-Y growth %
38.0%
₹ 3,211 million
Conversion %
90.2%
DSO
75 days

Quarter wise performance
33.5
* Q1 FY26 and Q4 FY25 Headcount includes BroadPath Headcount of 1,093 and 1,083 respectively (acquired in Q4 FY25) 
36.5 36.6 35.0
35.8 38.3 39.6 Headcount 
(‘000) 39.4
35.8
39.9
10
11,161 10,941 
12,602 12,832 12,233 
12.8% 11.5% 12.4% 12.9% 11.8%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
 -
 2,000
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25
Revenue INR M Adjusted PAT %
Headcount 
(‘000)
Impact of 
seasonality on 
Q1 vs Q4
April 23 to 
June 24
12,233 
13,250 
14,531 
15,685 15,389 
11.8% 12.3%
18.1%
15.3%
13.0%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
 -
 2,000
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
Revenue INR M Adjusted PAT %
April 24 to 
June 25
Increase in 
ETR in Q1 vs 
Q4

Financial performance snapshot – Q1 FY26
Revenue 
(INR Million) 
Y-o-Y Q-o-Q
25.8% -1.9%
Adjusted EBITDA* 
(INR Million)
Y-o-Y Q-o-Q
26.5% -11.7%
Adjusted PAT
(INR Million)
Y-o-Y Q-o-Q
38.0% -16.7%
Revenue ($M) 
Y-o-Y Q-o-Q
23.1% -0.8%
Adjusted EBITDA* 
($M)
Y-o-Y Q-o-Q
23.7% -10.7%
Adjusted PAT
($M)
Y-o-Y Q-o-Q
35.2% -15.8%
*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other 11
income (including forex gain/loss).
₹12,233
₹15,685 ₹15,389
Q1'25 Q4'25 Q1'26
$146.6
$181.8 $180.4
Q1'25 Q4'25 Q1'26
₹1,447
₹2,398
₹1,997
Q1'25 Q4'25 Q1'26
₹2,916
₹4,176
₹3,687
Q1'25 Q4'25 Q1'26
$34.9
$48.4
$43.2
Q1'25 Q4'25 Q1'26
$17.3
$27.8
$23.4
Q1'25 Q4'25 Q1'26

Financial performance snapshot – Long Term
Revenue 
(INR Million) 
FY25 YoY% TTM Jun YoY%
17.2% 21.1%
Adjusted EBITDA * 
(INR Million)
FY25 YoY% TTM Jun YoY%
28.4% 35.2%
Adjusted PAT
(INR Million)
FY25 YoY% TTM Jun YoY%
37.5% 46.3%
Revenue ($M) 
FY25 YoY% TTM Jun YoY%
14.9% 18.6%
Adjusted EBITDA* 
($M)
FY25 YoY% TTM Jun YoY%
25.9% 32.5%
Adjusted PAT
($M)
FY25 YoY% TTM Jun YoY%
34.8% 43.4%
*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other 12
income (including forex gain/loss).
₹11,436
₹14,685
₹11,432
₹15,456
FY24 FY25 TTM Jun'24 TTM Jun'25
₹47,536
₹55,699
₹48,608
₹58,855
FY24 FY25 TTM Jun'24 TTM Jun'25
₹5,896
₹8,107
₹5,919
₹8,657
FY24 FY25 TTM Jun'24 TTM Jun'25
$572.9
$658.3
$583.8
$692.1
FY24 FY25 TTM Jun'24 TTM Jun'25
$137.8
$173.6
$137.3
$181.8
FY24 FY25 TTM Jun'24 TTM Jun'25
$71.1
$95.8
$71.1
$101.9
FY24 FY25 TTM Jun'24 TTM Jun'25

Financial Indicators
Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares
Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities)
Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest 13
₹21,678
₹10,432
₹7,894
1.9x
0.71x
0.51x
 -
 0.50
 1.00
 1.50
 2.00
₹0
₹5,000
₹10,000
₹15,000
₹20,000
₹25,000
FY'24 FY'25 TTM Jun'25
Net Debt
Net Debt (in INR Million) Net Debt to Adjusted EBITDA
1.38 
1.76 1.85 
FY'24 FY'25 TTM Jun'25
Adjusted EPS (in INR)
87.2% 89.7% 90.2%
70.8%
80.5% 81.0%
FY'24 FY'25 YTD Jun'25
Cash Conversion (%)
OCF % FCF %
47%
55%
52%
FY'24 FY'25 TTM Jun'25
Adjusted ROCE %

Q1 FY26 Consolidated Profit and Loss
14
► Q1 26 Organic Revenue at INR 
14,429 Mn (YoY% 17.9% and 15.4% 
at constant currency YoY%)
Amt in INR M
Particulars Q1 FY26 Q4 FY25 Q1 FY25 YoY% QoQ%
Revenue from Operation 15,389 15,685 12,233 25.8% -1.9%
Employee benefits expense* 9,646 9,429 7,527
Other expenses^ 2,056 2,079 1,790
Adjusted EBITDA** 3,687 4,176 2,916 26.5% -11.7%
Adjusted EBITDA % 24.0% 26.6% 23.8%
Adjustments:
M&A Earnouts 155 207 124
SAR (stock appreciation right) – Non Cash 71 104 852
Other Income^^ 50 101 35
Forex Gain / (Loss) 49 -135 209
Reported EBITDA 3,560 3,832 2,184 63.0% -7.1%
Finance costs 274 298 374
Depreciation and amortisation 1,182 1,143 1,100
Profit Before Tax 2,104 2,390 710 196.3% -12.0%
Tax Expenses 618 564 487
Reported Profit After Tax 1,486 1,826 223 566.4% -18.6%
EPS 0.32 0.39 0.05 530.0% -18.6%
Adjusted PAT 1,997 2,398 1,447 38.0% -16.7%
Adjusted PAT % 13.0% 15.3% 11.8%
Adjusted EPS (Rs) 0.43 0.51 0.33 30.5% -16.7%
*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), 
^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately.
** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q1 FY26
Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax
Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible)
Adj C - Amortization of intangible assets that got created due to carveout of healthcare business from HGS
Adj PAT Bridge: Q1 FY26
INR Million
INR Million
15
₹1,486 ₹113 ₹71
₹327 ₹1,997
Reported PAT Adj A Adj B Adj C Adjusted PAT
₹3,560 ₹155 ₹71
-₹99
₹3,687
Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA

Go Forward Positions
• Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS
• Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33 
16
Amt in INR M
Particulars FY25 FY26 FY27 FY28 FY29 FY30
Closing Debt position 8,020 5,670
Debt Repayment 2,490 2,350 5,670
Interest Payment 751 535 285
Share based Payment awards 1,134 251 147 78 40
Earnouts Cost - DCI / Birch/ BroadPath 571 495 5
Intangibles Amortisation (A) 1,400 1,419 1,419 1,419 1,419 1,419
Intangibles Amortisation (B) 188 381 371 356 284 240

Balance Sheet as on 30th June 25
17
Amt in INR M
Particulars Jun 25 Mar 25
Property, plant and equipment 3,600 3,699
Capital-work-in-progress 19 0
Right-of-use assets 5,273 5,521
Goodwill 60,382 60,390
Other intangible assets 19,930 20,362
Trade receivables and Unbilled 12,994 12,668
Cash and cash equivalents 4,538 3,438
Deferred tax assets (net) 1,285 1,337
Other Assets 3,204 3,091
Total Assets 111,225 110,507
Equity 85,162 83,361
Borrowings 6,903 8,170
Lease liabilities 5,656 5,850
Trade payables 2,023 2,136
Deferred tax liabilities (net) 4,027 4,279
Other Liabilities 7,455 6,712
Total Liabilities 111,225 110,507

Cash Flow – Q1 FY26
18
Amt in INR M
Particulars Q1 FY26 FY25
Profit before tax for the period/ year 2,104 7,602
Adjustment for Non-Operating and Non-Cash items 1,552 6,982
Adjustment for working capital (254) (710)
Income taxes paid (net of refunds) (191) (1,734)
Net cash flows generated from operating activities (A) - OCF 3,211 12,141
Addition to Fixed Assets (326) (1,244)
Free Cash flow (FCF) 2,885 10,896
Cash paid for M&A 0 (4,825)
Pending Purchase consideration paid for healthcare business carveout 0 (3,756)
Others 81 184
Net cash flows (used in) investing activities (B) (245) (9,642)
Capital infused by promoter 0 3,708
Share Issue expense (paid)/ reimbursed 0 72
Repayment of Promoter borrowings (include Interest) (1,425) (4,567)
Repayment of lease liabilities (include Interest) (456) (1,774)
Net cash flows (used in) financing activities (C) (1,881) (2,561)
Net increase/ (decrease) in cash and cash equivalents (A+B+C) 1,086 (62)
Cash and cash equivalents at the beginning of the year/period 3,438 3,441
Effect of movement in exchange rates on cash and cash equivalents 15 58
Cash and cash equivalents at the end of the year/ period 4,538 3,438
Net cash flows generated from operating activities % (OCF on Reported EBITDA) 90.2% 89.7%
Free Cash flow % (FCF on Reported EBITDA) 81.0% 80.5%

P&L for Previous Quarters
19
Amt in INR M
Particulars Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26
Revenue from Operation 11,161 10,941 12,602 12,832 12,233 13,250 14,531 15,685 15,389
Employee benefits expense* 6,361 6,674 7,912 7,925 7,527 7,912 8,415 9,429 9,646
Other expenses^ 1,881 1,795 1,789 1,764 1,790 1,874 1,988 2,079 2,056
Adjusted EBITDA** 2,919 2,472 2,901 3,143 2,916 3,465 4,127 4,176 3,687
Adjusted EBITDA % 26.2% 22.6% 23.0% 24.5% 23.8% 26.1% 28.4% 26.6% 24.0%
Adjustments:
M&A Earnouts 282 132 71 70 124 120 120 207 155
SAR (stock appreciation right) – Non Cash 0 0 0 0 852 93 85 104 71
Other Income^^ 15 98 -8 8 35 153 99 101 50
Forex Gain / (Loss) 100 193 -164 38 209 -241 341 -135 49
Reported EBITDA 2,751 2,632 2,659 3,119 2,184 3,165 4,362 3,832 3,560
Finance costs 471 483 468 429 374 297 302 298 274
Depreciation and amortisation 1,661 1,715 1,756 1,760 1,100 1,264 1,162 1,143 1,182
Profit Before Tax 619 434 435 929 710 1,604 2,898 2,390 2,104
Tax Expenses 194 84 -271 127 487 431 729 564 618
Reported Profit After Tax 425 350 706 802 223 1,173 2,169 1,826 1,486
EPS 0.10 0.08 0.16 0.19 0.05 0.25 0.46 0.39 0.32
Adjusted PAT 1,424 1,254 1,567 1,651 1,447 1,636 2,626 2,398 1,997
Adjusted PAT % 12.8% 11.5% 12.4% 12.9% 11.8% 12.3% 18.1% 15.3% 13.0%
Adjusted EPS (Rs) 0.33 0.29 0.37 0.39 0.33 0.35 0.56 0.51 0.43
*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), 
^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately.
** Adjusted EBITDA represents EBITDA adjusted for earnouts payable for acquisitions (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income / forex gain or loss).

Thank You